Develops diagnostic tests for dermatological cancers. Offers DecisionDx-Melanoma, a test for assessing melanoma metastasis risk. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 38% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Sales run at $344.2M a year. A small number, but proof the product has real buyers.
There is $299.5M in the vault; even if every debt were paid off, $262.6M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $24.2M against $344.2M in annual sales.
Over the last 12 months, executives reported 207 sells against just 63 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, CSTL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CSTL is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.